Health ❯ Healthcare ❯ Biotechnology

Cancer Treatment

Immunotherapy Multiple Myeloma Bladder Cancer CAR T-cell Therapy CAR T Cell Therapy CAR-T Cell Therapy HER2-targeted Therapy Antibody-Drug Conjugates Cell Therapies Cancer Vaccines

3 ARTICLES

last mo.

Moderna Repositions as Broad mRNA Company After Investor Day Rally

The company has laid out a three‑horizon pipeline and commercial plan that could translate into multiple vaccine and oncology launches and near‑term regulatory catalysts.

6 ARTICLES

3mo ago

FDA Accepts ImmunityBio Filing to Expand ANKTIVA Use in Bladder Cancer

3 ARTICLES

3mo ago

CNS Pharmaceuticals Soars 215% on $22.5 Million Oversubscribed Private Placement

3 ARTICLES

3mo ago

Gilead Closes $7.8 Billion Arcellx Deal to Take Full Control of Anito‑cel

3 ARTICLES

4mo ago

Transgene Completes Phase 2 Randomization for Personalized Cancer Vaccine TG4050

4 ARTICLES

5mo ago

Iovance Shares Hit Record After UBS Doubles Price Target

9 ARTICLES

7mo ago

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

7 ARTICLES

7mo ago

ImmunityBio Sets 30-Day FDA Submission After Positive Meeting on Anktiva Expansion

8 ARTICLES

9mo ago

Johnson & Johnson to Buy Halda Therapeutics for $3.05 Billion to Bolster Oncology Pipeline

5 ARTICLES

9mo ago

Propanc Biopharma Lines Up Up to $100 Million From Hexstone to Launch Digital-Asset Treasury and Speed PRP Toward Trials

5 ARTICLES

10mo ago

Kite Pharma to Buy Interius for $350 Million, Adding In‑Vivo CAR‑T Platform

Cancer Treatment

Moderna Repositions as Broad mRNA Company After Investor Day Rally

FDA Accepts ImmunityBio Filing to Expand ANKTIVA Use in Bladder Cancer

CNS Pharmaceuticals Soars 215% on $22.5 Million Oversubscribed Private Placement

Gilead Closes $7.8 Billion Arcellx Deal to Take Full Control of Anito‑cel

Transgene Completes Phase 2 Randomization for Personalized Cancer Vaccine TG4050

Iovance Shares Hit Record After UBS Doubles Price Target

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

ImmunityBio Sets 30-Day FDA Submission After Positive Meeting on Anktiva Expansion

Johnson & Johnson to Buy Halda Therapeutics for $3.05 Billion to Bolster Oncology Pipeline

Propanc Biopharma Lines Up Up to $100 Million From Hexstone to Launch Digital-Asset Treasury and Speed PRP Toward Trials

Tubulis Raises €308 Million Series C to Accelerate Lead Cancer ADC

Genmab to Buy Merus for $8 Billion to Secure Petosemtamab Cancer Drug

Genmab Launches $8 Billion Bid for Utrecht Biotech Merus

Kite Pharma to Buy Interius for $350 Million, Adding In‑Vivo CAR‑T Platform